Finally, the combined treatment of Lumican-MSA-IL2 and IL12-MSA-Lumican potentiated anti-PD-1 increasing survival in multiple models and completely protecting cured mice from live tumor rechallenge (103). This evidence concerns the gene PDCD1 and neoplasm.